Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease.
Challenges in the Pathophysiology, Diagnosis, and Management of Intestinal Fibrosis in Inflammatory Bowel Disease.
复制标题
炎症性肠病中肠道纤维化的病理生理学，诊断和管理挑战。
DOI：
10.1053/j.gastro.2019.05.072
复制
发表时间：
2022-01
期刊：
影响因子：
29.4
通讯作者：
International Organization for Inflammatory Bowel Disease Fibrosis Working Group
中科院分区：
文献类型：
--
作者：
D'Haens G;Rieder F;Feagan BG;Higgins PDR;Panés J;Maaser C;Rogler G;Löwenberg M;van der Voort R;Pinzani M;Peyrin-Biroulet L;Danese S;International Organization for Inflammatory Bowel Disease Fibrosis Working Group
肠纤维化是炎症性肠病（IBD）的常见并发症，通常是慢性炎症的结果。虽然目前可用的抗炎治疗对克罗恩病（CD）的肠纤维化影响不大，但对病理生理学的了解和靶向纤维化途径的治疗方法的发展为未来带来了希望。关键挑战之一是如何在临床试验和药物批准的背景下定义和测量肠道纤维化的减少或逆转。国际炎症性肠病组织（IOIBD）于2018年12月19日和20日在荷兰阿姆斯特丹组织了一次研讨会，旨在回顾肠道纤维化的生物学背景，诊断，治疗和临床试验终点的现有知识。基础和临床科学家讨论了肠纤维化的病理生理学，狭窄性CD的生物标志物和成像方式的现状，以及该领域的最新临床研究。来自IBD领域以外的研究人员介绍了对其他器官（如皮肤、肝脏和肺）纤维化过程的理解进展。最后，讨论了IBD抗纤维化治疗临床试验的设计，优先考虑患者人群、患者报告结局（PRO）和成像。本报告概述了研讨会的主要结果、讨论和结论。
Intestinal fibrosis is a common complication of inflammatory bowel disease (IBD) that is usually the consequence of chronic inflammation. Although the currently available anti-inflammatory therapies have had little impact on intestinal fibrosis in Crohn’s disease (CD), increased understanding of the pathophysiology and the development of therapies targeting fibrogenic pathways hold promise for the future. One of the critical challenges is how reduction or reversal of intestinal fibrosis should be defined and measured in the setting of clinical trials and drug approval. The International Organization for Inflammatory Bowel Disease (IOIBD) organized a workshop in Amsterdam, The Netherlands, on December 19th and 20th, 2018 in an attempt to review the current knowledge of the biological background, diagnosis, treatment of intestinal fibrosis and clinical trial endpoints. Basic and clinical scientists discussed the pathophysiology of intestinal fibrosis, the current status of biomarkers and imaging modalities in stenosing CD, and recent clinical studies in this area. Researchers from outside of the IBD field presented advances in the understanding of fibrotic processes in other organs, such as the skin, liver and lungs. Lastly, the design of clinical trials with antifibrotic therapy for IBD was discussed, with priority on patient populations, patient reported outcomes (PROs) and imaging. This report summarizes the key findings, discussions and conclusions of the workshop.
登录
查看更多内容
影响因子：
7.6
作者：
Rieder F;Bettenworth D;Ma C;Parker CE;Williamson LA;Nelson SA;van Assche G;Di Sabatino A;Bouhnik Y;Stidham RW;Dignass A;Rogler G;Taylor SA;Stoker J;Rimola J;Baker ME;Fletcher JG;Panes J;Sandborn WJ;Feagan BG;Jairath V
通讯作者：
Jairath V
影响因子：
8
作者：
Chen, Wenqian;Lu, Cathy;Gui, Xianyong
通讯作者：
Gui, Xianyong
影响因子：
29.4
作者：
Danese, Silvio;Bonovas, Stefanos;Peyrin-Biroulet, Laurent
通讯作者：
Peyrin-Biroulet, Laurent
DOI：
10.1016/s0140-6736(17)30317-3
发表时间：
2017-04-29
期刊：
Lancet (London, England)
影响因子：
--
作者：
Kugathasan S;Denson LA;Walters TD;Kim MO;Marigorta UM;Schirmer M;Mondal K;Liu C;Griffiths A;Noe JD;Crandall WV;Snapper S;Rabizadeh S;Rosh JR;Shapiro JM;Guthery S;Mack DR;Kellermayer R;Kappelman MD;Steiner S;Moulton DE;Keljo D;Cohen S;Oliva-Hemker M;Heyman MB;Otley AR;Baker SS;Evans JS;Kirschner BS;Patel AS;Ziring D;Trapnell BC;Sylvester FA;Stephens MC;Baldassano RN;Markowitz JF;Cho J;Xavier RJ;Huttenhower C;Aronow BJ;Gibson G;Hyams JS;Dubinsky MC
通讯作者：
Dubinsky MC
影响因子：
24.5
作者：
Bouhnik Y;Carbonnel F;Laharie D;Stefanescu C;Hébuterne X;Abitbol V;Nachury M;Brixi H;Bourreille A;Picon L;Bourrier A;Allez M;Peyrin-Biroulet L;Moreau J;Savoye G;Fumery M;Nancey S;Roblin X;Altwegg R;Bouguen G;Bommelaer G;Danese S;Louis E;Zappa M;Mary JY;GETAID CREOLE Study Group
通讯作者：
GETAID CREOLE Study Group